Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
829
datasets available to search
ShareScore release 0.9.0
Dataset results
829 results for “Drug resistance”
Assessment of the Efficacy and Safety of 2 Doses of Retigabine Immediate Release (900 mg/Day and 600 mg/Day) Used as Adjunctive Therapy in Adult Asian Subjects With Drug-resistant Partial-onset Seizur
ClinicalTrials.gov study NCT01648101. IPD Sharing: YES. Countries: 7. Publications: 1.
Trial for the Treatment of Extensively Drug-Resistant Gram-negative Bacilli (OVERCOME)
ClinicalTrials.gov study NCT01597973. IPD Sharing: Not stated. Countries: 7. Publications: 1.
To Evaluate the Safety, Tolerability, and Efficacy of TMC207 as Part of an Individualized Multi-drug Resistant Tuberculosis (MDR-TB) Treatment Regimen in Participants With Sputum Smear-positive Pulmon
ClinicalTrials.gov study NCT00910871. IPD Sharing: Not stated. Countries: 12. Publications: 2.
Evidence for a role of Anopheles stephensi in the spread of drug- and diagnosis-resistant malaria in Africa
Open the record for dataset details and reuse information.
Data from: Fast drug rotation reduces bacterial resistance evolution in a microcosm experiment
Open the record for dataset details and reuse information.
Second-line drug resistance markers as proxy indicators of sputum culture conversion for samples tested in Uganda
Open the record for dataset details and reuse information.
Nano MOFs as targeted drug delivery agents to combat antibiotic resistant bacterial infections
Open the record for dataset details and reuse information.
Resistance to bacteriophage incurs a cost to virulence in drug resistant Acinetobacter baumannii
Open the record for dataset details and reuse information.
Outcomes and adverse events of pre- and extensively drug-resistant tuberculosis patients in Kinshasa, Democratique Republic of the Congo: retrospective cohort study
Open the record for dataset details and reuse information.
Investigating the consequences of the mating system for drug resistance evolution in C. elegans
Open the record for dataset details and reuse information.
Data from: Antibacterial activity of graphene oxide nanosheet against multi drug resistant superbugs isolated from infected patients
Open the record for dataset details and reuse information.
PfCRT mutations conferring piperaquine resistance in falciparum malaria shape the kinetics of quinoline drug binding and transport
Open the record for dataset details and reuse information.
Data from: Evaluating culture-free targeted next-generation sequencing for diagnosing drug-resistant tuberculosis: A multicentre clinical study of two end-to-end commercial workflows
Open the record for dataset details and reuse information.
Phenotypic and genotypic analysis of drug resistance in M. tuberculosis isolates in Gansu, China
Open the record for dataset details and reuse information.
Antibiotics can be used to contain drug-resistant bacteria by maintaining sufficiently large sensitive populations
Open the record for dataset details and reuse information.
Bacterial mediated green synthesis of silver nanoparticles and their antibacterial and antifungal activities against drug-resistant pathogens
Open the record for dataset details and reuse information.
Tumescent injections in subcutaneous pig tissue disperse fluids volumetrically and maintain elevated local concentrations of additives for several hours, suggesting a treatment for drug resistant wounds
Open the record for dataset details and reuse information.
Data from: Assessment of markers of antimalarial drug resistance in Plasmodium falciparum isolates from pregnant women in Lagos, Nigeria
Background: The use of antimalarial drugs for prevention and treatment is a major strategy in the prevention of malaria in pregnancy. Although sulphadoxine-pyrimethamine (SP) is currently recommended for intermittent preventive treatment of malaria during pregnancy in Nigeria, previously used drugs for prophylaxis such as chloroquine (CQ) and pyrimethamine are accessible as they are purchased over the counter. This study describes the markers of absence or presence of resistance to quinoline (Pfcrt and Pfmdr 1) and type 1 antifolate antimalarial medicines (Pfdhfr). Methods: Plasmodium falciparum-positive dried blood spots from pregnant women attending antenatal clinics for the first time during current pregnancy were investigated for the presence of mutations at codons 72–76 of Plasmodium falciparum chloroquine resistance transporter (Pfcrt) gene by real time polymerase chain reaction (PCR) using haplotype-specific probes. PCR followed by sequence analysis was used to identify mutations at codons 86, 184, 1034, 1042 and 1246 of P. falciparum multi-drug resistance-1 (Pfmdr1) gene; and codons 16, 50, 51, 59, 108, 140 and 164 of Pfdhfr gene. Results: Two haplotypes of Pfcrt (n = 54) were observed: CVMNK 13(24.2%) and CVIET 41 (75.9%) of the samples. The SVMNT haplotype was absent in this population. The Pfmdr1 (n = 28) haplotypes were NYSND 15(53.6%), YYSND 5(17.9%), NFSND 6(21.4%) and YFSND 2(7.1%). The Pfdhfr (n = 15) were ACNCSVI 4(26.7%), and ACICNSVI 1(6.7%) and ACIRNVI 10 (66.7%). The rate of occurrence of Pfcrt 76T, Pfdhfr108N, Pfmdr186Yand184F were 75.9%, 73.3%, 25% and 28.1% respectively. The Pfmdr1 86Y was associated with low parasitaemia (median = 71 parasites/μl, P = 0.024) while Pfcrt 76T was associated with young maternal age (mean 24.1 ± 4.5 years; P = 0.006). The median parasitaemia were similar (P>0.05) in wild and mutant strains of Pfcrt 76, Pfmdr1 184 and Pfdhfr 108. There was no association between gravidity or gestational age of the women and presence of mutations in the Pfcrt, Pfmdr1 or Pfdhfr genes (P>0.05). Conclusion: Markers of resistance to chloroquine and pyrimethamine were high, whereas cycloguanil-resistance marker was not present in the studied population. The low level of mutations in the Pfmdr1gene indicates likely efficacy of amodiaquine against malaria in pregnancy.
Data from: Delays and loss to follow up before treatment of drug-resistant TB following implementation of Xpert MTB/RIF in South Africa: a retrospective cohort study
Background: South Africa has a large burden of rifampicin-resistant tuberculosis (RR-TB), with 18,734 patients diagnosed in 2014. The number of diagnosed patients has increased substantially with the introduction of the Xpert MTB/RIF test, used for TB diagnosis for all patients with presumptive TB. Routine aggregate data suggest a large treatment gap (pre-treatment loss to follow up) between the numbers of laboratory confirmed RR-TB patients and those reported to have started second-line treatment. We aimed to assess the impact of Xpert MTB/RIF implementation on the delay to treatment initiation and loss to follow-up before second-line treatment for RR-TB across South Africa. Methods and findings: A nationwide retrospective cohort study was conducted to assess second-line treatment initiation and treatment delay among laboratory diagnosed RR-TB patients. Cohorts, including approximately 300 sequentially diagnosed RR-TB patients per South African province, were drawn from 2011 and 2013, before and after Xpert implementation. Patients with prior laboratory RR-TB diagnoses within 6 months and currently treated patients were excluded. Treatment initiation was determined through data linkage with national and local treatment registers, medical record review, interviews with healthcare staff, and direct contact with patients or household members. Additional laboratory data were used to track cases. National estimates of percentage treatment initiation and time to treatment were weighted to account for the sampling design. There were 2,508 and 2,528 eligible patients in the 2011 and 2013 cohorts respectively; 92% were newly diagnosed with RR-TB (new RR-TB, no prior RR-TB diagnoses). Nationally, among 2,340 and 2,311 new RR-TB patients in the 2011 and 2013 cohorts, 55% (95% CI 53-57) and 63% (95% CI 61-65) respectively started treatment within 6 months of their diagnostic specimen being sent (p<0.001). However, in 2013, there was no difference in the percentage of patients who initiated treatment at six months between the 1,368174 new RR-TB patients diagnosed by Xpert (62%, 95% CI 59-65) and the 943ose diagnosed by other methods (64%, 95% CI 61-67) (p=0.39). The median time to treatment decreased from 44 (IQR 20-69) days in 2011 to 22 (IQR 2-43) days in 2013 (p<0.001). In 2013, across the nine provinces, there were substantial variations in both treatment initiation (range 51-73% by six months) and median time to treatment (range 15-36 days, N=1,450), and only 53% of 1,448 new RR-TB who received treatmented patients were recorded on the national RR-TB register. This retrospective study is limited by the lack of information to assess reasons for non-initiation of treatment, particularly pre-treatment mortality data. Other limitations include the use of names and dates of birth to locate patient-level data, potentially resulting in missed treatment initiation among some patients. Conclusions: In 2013, there was a large treatment gap for RR-TB in South Africa which varied significantly across provinces. Xpert implementation, while reducing treatment delay, had not contributed substantially to reducing the treatment gap in 2013. However, given improved case detection with Xpert, overall a larger proportion of the total RR-TB burden has received treatment, with reduced delays. Nonetheless, strategies to further improve linkage to treatment for all diagnosed RR-TB patients are urgently required.
Amphibian resistance to chytridiomycosis increases following low virulence chytrid fungal infection or drug-mediated clearance
<p>Amphibian biodiversity is experiencing ongoing declines due in part to the infectious disease, chytridiomycosis. Efforts to mitigate the effects of the causal agent of chytridiomycosis, <em>Batrachochytrium dendrobatidis</em> (<em>Bd</em>), in the wild have not been wholly effective. Translocations are an important management tool for amphibians, and immunizations represent a possible strategy for preparing amphibians for release across a landscape where <em>Bd</em> exists.</p> <p>We evaluated the utility of using an isolate of <em>Bd</em> that was shown to be hypovirulent to the relict leopard frog (<em>Rana onca</em>) as a transmissible inoculum for promoting chytridiomycosis-resistance. We conducted a cohousing experiment to determine if the isolate we used could be passed between <em>R. onca </em>without increasing in virulence. We then followed with an experiment where frogs that were exposed to the hypovirulent isolate were then challenged with a virulent <em>Bd </em>isolate. In other experiments, we evaluated whether <em>Bd</em> infections followed by clearance with itraconazole (an antifungal) could increase resistance to chytridiomycosis in <em>R. onca</em> and <em>Rana pipiens</em> (northern leopard frog).</p> <p>We found that our hypovirulent <em>Bd</em> inoculation was transmissible between hosts, did not cause chytridiomycosis, and was effective at increasing chytridiomycosis-resistance. <em>Rana onca</em> inoculated with the hypovirulent <em>Bd</em> isolate had lower pathogen burdens and were 55 times more likely to survive infections by a virulent <em>Bd</em> isolate than non-inoculated frogs.</p> <p>For both species, prior exposure to <em>Bd</em> followed by infection clearance with itraconazole resulted in significantly increased survivorship and lower pathogen burdens as compared to controls that had no prior <em>Bd</em> exposure. <em>Rana onca</em> that were previously exposed to <em>Bd</em> were more than 15 times more likely to survive infections. Previously exposed <em>R. pipiens</em> survived in higher proportions than controls, but with weaker statistical support. </p>
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.